Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
November-2026 Volume 32 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2026 Volume 32 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Case Report Open Access

Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report

  • Authors:
    • Xue Bai
    • Liping Chen
    • Xuelian Chen
    • Dongcun Wang
    • Wenyan Kang
    • Lin Song
    • Meidi Liu
    • Caiwen Du
  • View Affiliations / Copyright

    Affiliations: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China, Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China
    Copyright: © Bai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Article Number: 507
    |
    Published online on: September 15, 2026
       https://doi.org/10.3892/ol.2026.15862
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:


Abstract

Patients with metastatic triple‑negative breast cancer (mTNBC) face a poor prognosis, with limited treatment options and short progression‑free survival. Chemotherapy remains a cornerstone in the treatment of mTNBC, but median overall survival is limited to 2‑3 years. Oral vinorelbine, whether used alone or in combination with other agents, has demonstrated efficacy in treating metastatic breast cancer. Anti‑angiogenic drugs also hold promise for managing advanced breast cancer. The present study reports a case of a patient with advanced TNBC and schizophrenia who progressed following adjuvant chemotherapy with anthracyclines and taxanes. Following recurrence and metastasis, the patient was treated with first‑line vinorelbine capsules combined with the small molecule anti‑angiogenic drug apatinib, and achieved partial remission. The initial time to first progression (due to patient‑led treatment discontinuation) was 14 months; however, despite multiple interruptions and rechallenges, the combination provided long‑term disease control spanning over 6 years from the start of first‑line therapy. Due to the high cost of apatinib, the patient discontinued it and switched to a regimen of vinorelbine capsules combined with capecitabine. The present case demonstrated that while the combination showed efficacy, treatment adherence and cost were major limitations. These findings indicated that vinorelbine capsules combined with apatinib offered notable efficacy and acceptable safety in this patient with schizophrenia, thus representing a potential therapeutic option for advanced TNBC, but further study is warranted. Notably, the combined treatment did not induce or worsen the patient's schizophrenia. Overall, the present case provided valuable insights in treating patients with breast cancer with schizophrenia.
View Figures

Figure 1

Chest and abdominal CT scans showing
metastatic lesions. (A-1) Chest wall metastasis (1.8×1.4 cm). (A-2)
Sternal bone destruction with soft tissue mass formation (4.2×3.5
cm). (A-3) Left supraclavicular lymph node metastasis (2.0×2.5 cm).
(A-4) Mediastinal lymph node metastasis (2.2×1.5 cm). (A-5) Liver
metastasis (3.0×3.0 cm). Red arrows indicate metastases. CT,
computed tomography.

Figure 2

Histopathological and
immunohistochemical findings of metastatic breast cancer in the
lymph node: (A) H&E staining showing destruction of lymph node
structure with infiltrative growth of metastatic breast carcinoma
cells (magnification, ×40). (B) H&E staining showing
pleomorphic cancer cells with mitotic figures, apoptosis and
necrosis (magnification, ×400). (C) Immunohistochemistry for ER
(negative; magnification, ×100). (D) Immunohistochemistry for PR
(negative; magnification, ×100). (E) Immunohistochemistry for HER2
(2+; magnification, ×400).

Figure 3

Immunohistochemical and FISH analysis
of metastatic breast cancer: (A) Immunohistochemistry for Ki-67
(proliferation index ~80%; magnification, ×100). (B)
Immunohistochemistry for p53 (100% positive, mutant type;
magnification, ×100). (C) Immunohistochemistry for E-cadherin
(positive; magnification, ×100). (D) FISH analysis for HER2 gene
(no amplification, HER2:CEP17 ratio <2; magnification, ×400).
(E) Immunohistochemistry for AR (30% positive cells, moderate
staining intensity; magnification, ×200). (F) Immunohistochemistry
for TOPOIIA (~50% positive; magnification, ×200). AR, androgen
receptor; CEP17, chromosome enumeration probe 17; FISH,
fluorescence in situ hybridization; HER2, human epidermal growth
factor receptor 2; Ki-67, marker of proliferation Ki-67; p53, tumor
protein p53; TOPOIIA, DNA topoisomerase II α.

Figure 4

Chest and abdominal CT scans showing
response to oral vinorelbine combined with apatinib: Baseline
images and images after two cycles of treatment are shown. The
efficacy was evaluated as partial response. (A-1, B-1) Chest wall
metastasis, (A-2, B-2) Sternal bone destruction with soft tissue
mass formation, (A-3, B-3) Left supraclavicular lymph node
metastasis, (A-4, B-4) Mediastinal lymph node metastasis and (A-5,
B-5) Liver metastasis. Metastatic lesion size reduction: (A-1)
1.8×1.4 cm to (B-1): 0 cm, (A-2) 4.2×3.5 cm to (B-2): 1×1 cm, (A-3)
2.0×2.5 cm to (B-3): 1.2×1.0 cm, (A-4) 2.2×1.5 cm to (B-4): 0.8×0.5
cm and (A-5) 3.0×3.0 cm to (B-5): 1.0×0.5 cm. Red arrows indicate
metastases. CT, computed tomography.

Figure 5

Chest and abdominal CT scans showing
sustained partial response after multiple cycles of oral
vinorelbine combined with apatinib. (A-1, B-1 and C-1) Chest wall
metastasis. (A-2, B-2 and C-2) Sternal bone destruction with soft
tissue mass formation. (A-3, B-3 and C-3) Left supraclavicular
lymph node metastasis. (A-4, B-4 and C-3) Mediastinal lymph node
metastasis. (A-5, B-5 and C-3) Liver metastasis. (A-1, A-2, A-3,
A-4 and A-5) Baseline images (January 2018), (B-1, B-2, B-3, B-4
and B-5) images after two cycles (March 2018), and (C-1, C-2, C-3,
C-4 and C-5) images after multiple cycles (December 2018) are
shown. Metastatic lesion size reduction: (A-1) 1.8×1.4 cm to (B-1)
0 cm to (C-1) 0 cm, (A-2) 4.2×3.5 cm to (B-2) 1×1 cm to (C-2) 1×0.8
cm, (A-3) 2.0×2.5 cm to (B-3) 1.2×1.0 cm to (C-3) 1.0×1.0 cm, (A-4)
2.2×1.5 cm to (B-4) 0.8×0.5 cm to (C-4) 0.8×0.4 cm and (A-5)
3.0×3.0 cm to (B-5) 1.0×0.5 cm to (C-5) 0 cm. CT, computed
tomography.

Figure 6

Chest and abdominal CT scans showing
disease progression after discontinuation of oral vinorelbine and
apatinib. (A-1 and B-1) Chest wall metastasis. (A-2 and B-2)
Sternal bone destruction with soft-tissue mass formation. (A-3 and
B-3) Left supraclavicular lymph node metastasis. (A-4 and B-4)
Mediastinal lymph node metastasis. (A-5 and B-5) Liver metastasis.
(A-1, A-2, A-3, A-4 and A-5) Baseline images (December 2018) and
(B-1, B-2, B-3, B-4 and B-5) images after treatment discontinuation
(March 2019) are shown. Metastatic lesion size enlargement: (A-1) 0
to (B-1) 0 cm, (A-2) 1×0.8 to (B-2) 2×1.5 cm, (A-3) 1.0×1.0 to
(B-3) 2×2.2 cm, (A-4) 0.8×0.4 to (B-4) 2.0×1.5 cm and (A-5) 0 cm to
(B-5) 0 cm. CT, computed tomography.

Figure 7

Chest and abdominal CT scans showing
re-partial response after resuming oral vinorelbine and apatinib:
(A-1 and B-1) Chest wall metastasis. (A-2 and B-2) Sternal bone
destruction with soft-tissue mass formation. (A-3 and B-3) Left
supraclavicular lymph node metastasis. (A-4 and B-4) Mediastinal
lymph node metastasis. (A-5 and B-5) Liver metastasis. (A-1, A-2,
A-3, A-4 and A-5) Baseline images (March 2019) and (B-1, B-2, B-3,
B-4 and B-5) images after two cycles of treatment (May 2019) are
shown. Metastatic lesion size reduction: (A-1) 0 cm to (B-1) 0 cm,
(A-2) 2×1.5 cm to (B-2) 1×0.8 cm, (A-3) 2×2.2 cm to (B-3) 1×1 cm,
(A-4) 2.0×1.5 cm to (B-4)1.8×1.0 cm and (A-5) 0 cm to (B-5) 0 cm.
CT, computed tomography.

Figure 8

Chest and abdominal CT scans showing
sustained partial response after multiple cycles of resumed
treatment. (A-1 and B-1) Chest wall metastasis. (A-2 and B-2)
Sternal bone destruction with soft-tissue mass formation. (A-3 and
B-3) Left supraclavicular lymph node metastasis. (A-4 and B-4)
Mediastinal lymph node metastasis. (A-5 and B-5) Liver metastasis.
(A-1, A-2, A-3, A-4 and A-5) Baseline images (May 2019) and (B-1,
B-2, B-3, B-4 and B-5) images after multiple cycles (January 2020)
are shown. Metastatic lesion size reduction: (A-1) 0 cm to (B-1) 0
cm, (A-2) 1×0.8 cm to (B-2) 0.5×0.5 cm, (A-3) 1×1 cm to (B-3) 1×1
cm, (A-4) 1.8×1.0 cm to (B-4) 1.8×0.9 cm and (A-5) 0 cm to (B-5) 0
cm. CT, computed tomography.

Figure 9

Chest and abdominal CT scans showing
disease progression after the second discontinuation of oral
vinorelbine and apatinib. (A-1 and B-1) Chest wall metastasis. (A-2
and B-2) Sternal bone destruction with soft-tissue mass formation.
(A-3 and B-3) Left supraclavicular lymph node metastasis. (A-4 and
B-4) Mediastinal lymph node metastasis. (A-5 and B-5) Liver
metastasis. (A-1, A-2, A-3, A-4 and A-5) Baseline images (January
2020) and (B-1, B-2, B-3, B-4 and B-5) images after treatment
discontinuation (April 2020) are shown. Metastatic lesion size
enlargement: (A-1) 0 cm to (B-1) 0 cm, (A-2) 0.5×0.5 cm to (B-2)
2×2 cm, (A-3) 1×1 cm to (B-3) 1.5×1.2 cm, (A-4) 1.8×0.9 cm to (B-4)
2×1.2 cm and (A-5) 0 cm to (B-5) 0 cm. CT, computed tomography.

Figure 10

Chest and abdominal CT scans showing
re-partial response after resuming oral vinorelbine and apatinib
during the COVID-19 pandemic. (A-1 and B-1) Chest wall metastasis.
(A-2 and B-2) Sternal bone destruction with soft-tissue mass
formation. (A-3 and B-3) Left supraclavicular lymph node
metastasis. (A-4 and B-4) Mediastinal lymph node metastasis. (A-5
and B-5) Liver metastasis. (A-1, A-2, A-3, A-4 and A-5) Baseline
images (April 2020) and (B-1, B-2, B-3, B-4 and B-5) images after
one cycle of treatment (May 2020) are shown. Metastatic lesion size
reduction: (A-1) 0 cm to (B-1) 0 cm, (A-2) 2×2 cm to (B-2) 0.8×0.7
cm, (A-3) 1.5×1.2 cm to (B-3) 1.0×0.8 cm, (A-4) 2×1.2 cm to (B-4)
1.2×0.8 cm and (A-5) 0 cm to (B-5) 0 cm. CT, computed
tomography.

Figure 11

Chest and abdominal CT scans showing
disease progression due to irregular use of oral vinorelbine and
apatinib. (A-1 and B-1) Chest wall metastasis. (A-2 and B-2)
Sternal bone destruction with soft-tissue mass formation. (A-3 and
B-3) Left supraclavicular lymph node metastasis. (A-4 and B-4)
Mediastinal lymph node metastasis. (A-5 and B-5) Liver metastasis.
(A-1, A-2, A-3, A-4 and A-5) Baseline images (May 2020) and (B-1,
B-2, B-3, B-4 and B-5) images after irregular treatment (February
2023) are shown. Metastatic lesion size enlargement: (A-1) 0 cm to
(B-1) 0 cm, (A-2) 0.8×0.7 cm to (B-2) 1.8×2 cm, (A-3) 1.0×0.8 cm to
(B-3) 1.5×1.4 cm, (A-4) 1.2×0.8 cm to (B-4) 1.8×1.1 cm and (A-5) 0
cm to (B-5) 0 cm. CT, computed tomography.

Figure 12

Chest and abdominal CT scans showing
tumor stabilization with vinorelbine monotherapy. (A-1 and B-1)
Chest wall metastasis. (A-2 and B-2) Sternal bone destruction with
soft-tissue mass formation. (A-3 and B-3) Left supraclavicular
lymph node metastasis. (A-4 and B-4) Mediastinal lymph node
metastasis. (A-5 and B-5) Liver metastasis. (A-1, A-2, A-3, A-4 and
A-5) Baseline images (February 2023) and (B-1, B-2, B-3, B-4 and
B-5) images after vinorelbine treatment (July 2023) are shown.
Metastatic lesion size reduction: (A-1) 0 cm to (B-1) 0 cm (A-2)
1.8×2 cm to (B-2) 1.6×1.7 cm, (A-3) 1.5×1.4 cm to (B-3) 1.4×1.4 cm,
(A-4) 1.8×1.1 cm to (B-4) 1.6×1.0 cm and (A-5) 0 cm to (B-5) 0 cm.
CT, computed tomography.

Figure 13

Chest and abdominal CT scans showing
disease progression with vinorelbine monotherapy. (A-1 and B-1)
Chest wall metastasis. (A-2 and B-2) Sternal bone destruction with
soft-tissue mass formation. (A-3 and B-3) Left supraclavicular
lymph node metastasis. (A-4 and B-4) Mediastinal lymph node
metastasis. (A-5 and B-5) Liver metastasis. (A-1, A-2, A-3, A-4 and
A-5) Baseline images (July 2023) and (B-1, B-2, B-3, B-4 and B-5)
images after vinorelbine treatment (January 2024) are shown.
Metastatic lesion size enlargement: (A-1) 0 cm to (B-1) 0 cm, (A-2)
1.6×1.7 cm to (B-2) 2.1×2.0 cm, (A-3) 1.4×1.4 cm to (B-3) 2.0×1.9
cm, (A-4) 1.6×1.0 cm to (B-4) 2.4×2.0 cm and (A-5) 0 cm to (B-5) 0
cm. CT, computed tomography.

Figure 14

Chest and abdominal CT scans showing
steady augmentation (SDb) with vinorelbine combined with
capecitabine. (A-1 and B-1) Chest wall metastasis. (A-2 and B-2)
Sternal bone destruction with soft-tissue mass formation. (A-3 and
B-3) Left supraclavicular lymph node metastasis. (A-4 and B-4)
Mediastinal lymph node metastasis. (A-5 and B-5) Liver metastasis.
(A-1, A-2, A-3, A-4 and A-5) Baseline images (January 2024) and
(B-1, B-2, B-3, B-4 and B-5) images after treatment (April 2024)
are shown. Metastatic lesion size enlargement: (A-1) 0 cm to (B-1)
0 cm, (A-2) 2.1×2.0 cm to (B-2) 2.1×2.2 cm, (A-3) 2.0×1.9 cm to
(B-3) 2.0×2.2 cm, (A-4) 2.4×2.0 cm to (B-4) 2.5×2.1 cm, (A-5) 0 cm
to (B-5) 0 cm. CT, computed tomography.
View References

1 

Tang S, Wang K, Zheng K, Liu J, Zhang H, Tan M, Li H, Li H, Tan X, Liu D and Guo R: Clinical and pathological response to neoadjuvant chemotherapy with different chemotherapy regimens predicts the outcome of locally advanced breast cancer. Gland Surg. 9:1415–1427. 2020. View Article : Google Scholar : PubMed/NCBI

2 

Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, et al: Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the brightness randomized clinical trial. JAMA Surg. 155:e1954102020. View Article : Google Scholar : PubMed/NCBI

3 

Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, et al: Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: A phase 3 randomized clinical trial. JAMA Oncol. 6:1390–1396. 2020. View Article : Google Scholar : PubMed/NCBI

4 

Kumar H, Gupta NV, Jain R, Madhunapantula SV, Babu CS, Kesharwani SS, Dey S and Jain V: A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res. 54:271–292. 2023. View Article : Google Scholar : PubMed/NCBI

5 

Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, Cheng Y, Ouyang Q, Wang X, Chen Z, et al: Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer. 112:57–65. 2019. View Article : Google Scholar : PubMed/NCBI

6 

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet. 377:914–923. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S and Shao Z: A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer. Cancer Biol Ther. 16:225–232. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Laessig D, Stemmler HJ, Vehling-Kaiser U, Fasching PA, Melchert F, Kolbl H, Stauch M, Maubach P, Scharl A, Morack G, et al: Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology. 73:407–414. 2007. View Article : Google Scholar : PubMed/NCBI

9 

Sharma P: Biology and management of patients with triple-negative breast cancer. Oncologist. 21:1050–1062. 2016. View Article : Google Scholar : PubMed/NCBI

10 

Dufort A and Zipursky RB: Understanding and managing treatment adherence in schizophrenia. Clin Schizophr Relat Psychoses. 2019 Jan 3;Online ahead of print. View Article : Google Scholar : PubMed/NCBI

11 

Whiting D, Lichtenstein P and Fazel S: Violence and mental disorders: A structured review of associations by individual diagnoses, risk factors, and risk assessment. Lancet Psychiatry. 8:150–161. 2021. View Article : Google Scholar : PubMed/NCBI

12 

Zhao S, Ma D, Xiao Y, Li XM, Ma JL, Zhang H, Xu XL, Lv H, Jiang WH, Yang WT, et al: Molecular subtyping of triple-negative breast cancers by immunohistochemistry: Molecular basis and clinical relevance. Oncologist. 25:e1481–e1491. 2020. View Article : Google Scholar : PubMed/NCBI

13 

Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J and Lou L: YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 135:1961–1969. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, Su S, Wang Q, Jin L, Wang Y, et al: Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: An open-label phase II trial. J Immunother Cancer. 8:e0006962020. View Article : Google Scholar : PubMed/NCBI

16 

Liu J, Wang Y, Tian Z, Lin Y, Li H, Zhu Z, Liu Q, Su S, Zeng Y, Jia W, et al: Multicenter phase II trial of camrelizumab combined with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun. 13:30112022. View Article : Google Scholar : PubMed/NCBI

17 

Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP and Meininger V: Biochemical effects of navelbine on tubulin and associated proteins. Semin Oncol. 16 (Suppl 4):9–14. 1989.PubMed/NCBI

18 

Maral R, Bourut C, Chenu E and Mathé G: Experimental antitumor activity of 5′-nor-anhydrovinblastine navelbine. Cancer Lett. 22:49–54. 1984. View Article : Google Scholar : PubMed/NCBI

19 

Goa KL and Faulds D: Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging. 5:200–234. 1994. View Article : Google Scholar : PubMed/NCBI

20 

Barni S, Freier B, Garau I, Mouysset JL, Sediva M, Zamagni C, Berdeaux G and de Almeida Agudo C: Burden of advanced breast cancer for patients and caregivers in Europe: Comparison of two treatment forms of vinorelbine, oral and intravenous. Curr Med Res Opin. 32:1807–1812. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Aapro M and Finek J: Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results. Cancer Treat Rev. 38:120–126. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K and Trillet-Lenoir V: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 21:35–40. 2003.PubMed/NCBI

23 

Mansour M and Mourad C: Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer. Cancer Chemother Pharmacol. 72:429–435. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N and Villanova G: All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: An international phase II trial. Br J Cancer. 101:232–237. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Nolè F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M and Goldhirsch A: Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 64:673–680. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Picchioni MM and Murray RM: Schizophrenia. BMJ. 335:91–95. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Bushe CJ, Bradley AJ, Wildgust HJ and Hodgson RE: Schizophrenia and breast cancer incidence: A systematic review of clinical studies. Schizophr Res. 114:6–16. 2009. View Article : Google Scholar : PubMed/NCBI

28 

Catalá-López F, Suárez-Pinilla M, Suárez-Pinilla P, Valderas JM, Gómez-Beneyto M, Martinez S, Balanzá-Martínez V, Climent J, Valencia A, McGrath J, et al: Inverse and direct cancer comorbidity in people with central nervous system disorders: A meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom. 83:89–105. 2014. View Article : Google Scholar : PubMed/NCBI

29 

Zhuo C and Triplett PT: Association of schizophrenia with the risk of breast cancer incidence: A meta-analysis. JAMA Psychiatry. 75:363–369. 2018. View Article : Google Scholar : PubMed/NCBI

30 

Sharma A, Ngan S, Nandoskar A, Lowdell C, Lewis JS, Hogben K, Coombes RC and Stebbing J: Schizophrenia does not adversely affect the treatment of women with breast cancer: A cohort study. Breast. 19:410–412. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ and Goodwin FK: The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 50:85–94. 1993. View Article : Google Scholar : PubMed/NCBI

32 

Saha S, Chant D, Welham J and McGrath J: A systematic review of the prevalence of schizophrenia. PLoS Med. 2:e1412005. View Article : Google Scholar : PubMed/NCBI

33 

McGrath J, Saha S, Welham J, El Saadi O, MacCauley C and Chant D: A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2:132004. View Article : Google Scholar : PubMed/NCBI

34 

Gion M, Blancas I, Cortez-Castedo P, Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza I, Recalde S, et al: Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: The ATRACTIB phase 2 trial. Nat Med. 31:2746–2754. 2025. View Article : Google Scholar : PubMed/NCBI

35 

Hui Y, Wang Y, Nam G, Fanion J, Sturtevant A, Lombardo KA and Resnick MB: Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: Assessment of immunohistochemical markers. Hum Pathol. 77:11–19. 2018. View Article : Google Scholar : PubMed/NCBI

36 

Liu XH, Man YN, Cao R, Liu C and Wu XZ: Individualized chemotherapy based on organ selectivity: A retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer. Curr Med Res Opin. 30:1017–1024. 2014. View Article : Google Scholar : PubMed/NCBI

37 

Shi J, Wu L, Zheng W, Wen W, Wang S, Shu X, Long J, Shen CY, Wu PE, Saloustros E, et al: Genetic evidence for the association between schizophrenia and breast cancer. J Psychiatr Brain Sci. 3:72018.PubMed/NCBI

38 

Hwang M, Farasatpour M, Williams CD, Margenthaler JA, Virgo KS and Johnson FE: Adjuvant chemotherapy for breast cancer in patients with schizophrenia. Oncol Lett. 3:845–850. 2012.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Bai X, Chen L, Chen X, Wang D, Kang W, Song L, Liu M and Du C: Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report. Oncol Lett 32: 507, 2026.
APA
Bai, X., Chen, L., Chen, X., Wang, D., Kang, W., Song, L. ... Du, C. (2026). Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report. Oncology Letters, 32, 507. https://doi.org/10.3892/ol.2026.15862
MLA
Bai, X., Chen, L., Chen, X., Wang, D., Kang, W., Song, L., Liu, M., Du, C."Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report". Oncology Letters 32.5 (2026): 507.
Chicago
Bai, X., Chen, L., Chen, X., Wang, D., Kang, W., Song, L., Liu, M., Du, C."Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report". Oncology Letters 32, no. 5 (2026): 507. https://doi.org/10.3892/ol.2026.15862
Copy and paste a formatted citation
x
Spandidos Publications style
Bai X, Chen L, Chen X, Wang D, Kang W, Song L, Liu M and Du C: Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report. Oncol Lett 32: 507, 2026.
APA
Bai, X., Chen, L., Chen, X., Wang, D., Kang, W., Song, L. ... Du, C. (2026). Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report. Oncology Letters, 32, 507. https://doi.org/10.3892/ol.2026.15862
MLA
Bai, X., Chen, L., Chen, X., Wang, D., Kang, W., Song, L., Liu, M., Du, C."Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report". Oncology Letters 32.5 (2026): 507.
Chicago
Bai, X., Chen, L., Chen, X., Wang, D., Kang, W., Song, L., Liu, M., Du, C."Combination of vinorelbine capsules and the small molecule anti‑angiogenic drug apatinib for first‑line treatment of advanced triple‑negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report". Oncology Letters 32, no. 5 (2026): 507. https://doi.org/10.3892/ol.2026.15862
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team